Loading patent…
AssigneeOncomatryx Biopharma, S.L.
InventorsMyriam Fabre, Cristina Ferrer, Ribas Ignacio Garcia, Ruiz Pablo Moreno, Laureano Simon
Estimating the term…
The present invention relates to anti-Fibroblast Activating Protein α (FAP)-targeted antibody-drug conjugates (ADCs), in particular anti-FAP antibody-cytolysin conjugates having the formula A-(L-D)p, or a pharmaceutically acceptable salt or solvate thereof, wherein A is an anti-FAP antibody that selectively binds FAP, L is a linker, D is a drug comprising a cytolysin and p is 1 to 10, for use in a method of treatment of FAP+ sarcoma in a mammalian subject. In vitro methods of selecting sarcoma patients for treatment with a FAP-targeted ADC are also disclosed.
An anti-Fibroblast Activating Protein α (FAP) antibody-cytolysin conjugate having the formula A-(L-D)p, or a pharmaceutically acceptable salt or solvate thereof, wherein A is an anti-FAP antibody that selectively binds FAP, L is a linker, D is a drug comprising a cytolysin and p is 1 to 10, for use in a method of treatment of sarcoma in a mammalian subject, wherein the sarcoma is characterised by FAP expression in the tumour.
The conjugate for the use according to any preceding claim, wherein the conjugate is administered intravenously;
An in vitro method of selecting a subject that has been determined to have sarcoma for treatment with an anti-FAP ADC, comprising:
Dependencies are inferred from the claim text.